Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438832 | PMC |
| http://dx.doi.org/10.4103/joacp.JOACP_587_20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retraction notice to "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial" [International Journal of Antimicrobial Agents 56 (2020), 105949].
Int J Antimicrob Agents
December 2024
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address:
Cardiac findings in a phase II double-blind randomized placebo-controlled trial of combination therapy (HAZDPac) to treat COVID-19 patients.
BMC Cardiovasc Disord
December 2024
Community Memorial Hospital, Ventura, CA, USA.
Objective: Hydroxychloroquine paired with Azithromycin, Vitamin C, Vitamin D, and Zinc (HAZDPac), was used as a multidrug therapy method to treat COVID-19 illness and superimposed secondary bacterial pneumonia. Concerns have been raised though about such combinations regarding cardiac QTc interval prolongation and risks of arrhythmias, which we set out to address in this study.
Design: We evaluated cardiac safety in a Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infections study, conducted by ProgenaBiome.
Risk factors of COVID-19 related hospitalization of pediatric patients with rheumatic diseases: a systematic review and meta-analysis.
Rheumatology (Oxford)
December 2024
Department of Pediatrics, School of Medicine, George Washington University, Washington, DC, USA.
Objective: Among adults who develop Coronavirus Disease 2019 (COVID-19), those with rheumatic diseases (RDs) have similar hospitalization rates compared with those without RDs. Similar comparisons are lacking in children, due to the overall rarity of COVID-19-related hospitalization in this population. We aimed to examine the risk factors for COVID-19-related hospitalization in pediatric patients with RDs.
View Article and Find Full Text PDFRivers at risks: The interplay of "COVID kit" medication misuse and urban waterway contaminants.
Chemosphere
December 2024
Laboratório de Fisiologia de Plantas sob Estresse, Departamento de Botânica, Setor de Ciências Biológicas, Universidade Federal do Paraná, Avenida Coronel Francisco H. dos Santos, 100, Centro Politécnico Jardim das Américas, C. P. 19031, Curitiba, 81531-980, Paraná, Brazil. Electronic address:
This study investigates the environmental impact of the widespread use of "COVID Kit" drugs-azithromycin (AZI), ivermectin (IVE), and hydroxychloroquine (HCQ)-in urban rivers of Curitiba in Brazil, during and after the COVID-19 pandemic. The research focuses on the occurrence and concentrations of these pharmaceuticals in water and sediment samples collected from key urban rivers. Concentrations of AZI, IVE, and HCQ in water ranged from 326 to 3340 ng/L, 130-3340 ng/L, and 304-3314 ng/L, respectively, while in sediment, they ranged from 18 to 249 ng/g, 21-480 ng/g, and 38-673 ng/g, respectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!